Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): Induction of protective tolerance in primed animals

Clinical and Experimental Immunology

Volumn 111, Issue 3, 1998, Pages 506-512

  Shi, F D ^b   Bai, X F ^b   Li, H L ^b   Huang, Y M ^b   Van Der Meide, P H ^a   Link, H ^b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokine; Experimental autoimmune myasthenia gravis; Mucosal tolerance; Th1 cells; Th2 cells

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY SPECIFICITY; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; LYMPHOCYTE ACTIVATION; MYASTHENIA GRAVIS; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; RNA, MESSENGER; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; TORPEDO;

EID: 0031924547     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1998.00521.x     Document Type: Article

References (54)

1. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997; 18:335-243.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797-810.
3. Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann NY Acad Sci 1976; 274:283-99.
4. Asthana D, Fujii Y, Huston Y, Lindstrom J. Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis is mediated by IL-4 and antigen-specific T cell factors. Clin Immunol Immunopathol 1993; 67:240-8.
5. Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44:209-14.
6. Wang ZY, Link H, Ljungdahl Å, Höjeberg B, Link J, Qiao J, Melms A, Olsson T. Induction of interferon-γ, interleukin-4 and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell Immunol 1994; 157:353-68.
7. Okumura S, McIntosh K, Drachman DB. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994; 36:704-13.
8. Ma CG, Zhang GX, Xiao BG, Link J, Olsson T, Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol 1995; 58:51-60.
9. Lindstrom J, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurol 1976; 26:1054-9.
10. Deibler GE, Martensson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972; 2:139-64.
11. Lennon VA, Lambert EH, Leiby KR, Okarma TB, Talib S. Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991; 146:2245-8.
12. Christadoss P, Lindstrom J, Munro S, Talal N. Musele acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlation with cellular, humoral and clinical responses. J Neuroimmunol 1985; 8:29-41.
13. Wang ZY, Link H, Huang WX. T-cell immunity to acetylcholine receptor and its subunits in Lewis rats over the course of experimental autoimmune myasthenia gravis. Scand J Immunol 1993; 37:615-22.
14. Macdonald RA, Hosking CS, Jones CL. The measurement of relative antibody affinity by ELISA using thicyanate elution. J Immunol Methods 1988; 106:191-4.
15. Lindstrom J, Einarson B, Tzartos S. Production and assay of antibodies to AChR. Methods Enzymol 1981; 74:432-60.
16. Kao I, Drachman DB. Myasthenic immunoglohulin accelerates acetylcholine receptor degradation. Sci 1977; 196:527-9.
17. Dijkema R, van der Meide PH, Dubbeld M, Wubben J, Schellekens H. Cloning, expression and purification of rat IFN-γ. Methods Enzymol 1986; 119:453-8.
18. McKnight AJ, Barclay AN, Mason DW. Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4' T cells. Eur J Immunol 1991; 21:1187-94.
19. Moore KW, Vieia P, Fiorentino DF, Trounsteine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Sci 1990; 248:1230-5.
20. Derynek R, Jarret JA. Chen EY et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316:701-3.
21. Shirai T, Shimizu N, Horiguchi S, Jto H. Rat TNF alpha. Agric Biol Chem 1989; 53:1733-9.
22. Alastair J, Bradley JA. Interleukin-12 induces interferon-γ-dependent switching of IgG alloantibody subclass. Eur J Immunol 1996; 26:1217-21.
23. Mussener Å, Lorentzen JC, Kleinau S, Klareskog L. Altered Th1/Th2 balance associated with non-major histocompatibility complex gene in collagen-induced arthritis in resistant and non-resistant rat strains. Eur J Immunol 1997; 27:695-9.
24. Hucho F, Tsetlin VI, Machold J. The emerging three-dimensional structure of a receptor: the nieotinic acetylcholine receptor. Eur J Biochem 1996; 239:539-57.
25. Drachman DB. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 1996; 19:1239-51.
26. Vincent A, Jacobson L, Shillito P. Response to human acetylcholine receptor α-139-199: determinant spreading initiales autoimmunity to sell-antigen in rabbits. Immunol Letters 1994; 39:269-75.
27. Aguis MA, Twaddle GM, Fairclough RH. Epitope spreading in experimental autoimmune myasthenia gravis (Abstr.). IX International Conference on Myasthenia Gravis and Related Disorders. Santa Monica: 1997:4.
28. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-46.
29. Papp I, Wieder KJ, Sablinski T, O'Connel PJ, Milford EL, Strom TB, Kupiec Weglinski JW. Evidence for functional heterogeneity of rat CD4 T cells in vivo. Differential expression of IL-2 and IL-4 mRNA in recipient of cardiac allografts. J Immunol 1992; 148:1308-14.
30. McKnight AJ, Barclay AN, Mason DW. Molecular cloning of rat interleukin 4 cDNA and analysis of the cytokine repertoire of subsets of CD4 T cells. Eur J Immunol 1991; 21:1187-94.
31. Fujii Y, Lindstrom JM, Regulation of antibody production by helper T cell clones in experimental autoimmune myasthenia gravis, J Immunol 1988; 141:3361-9.
32. Mosmann TR, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond MW. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6 and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid radioimmunoadsorbent assay. J Immunol 1990; 145:2938-45.
33. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, De Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
34. Peterson JD, Karpus WJ, Clatch RJ, Miller SD. Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus, Eur J Immunol 1993; 23:46-55.
35. Ohtsuru I, Matsuo H, Fukudome T, Suenags A, Tsujihata M, Nagataki S. Split tolerance induction by intrathymic injection of acetylcholine receptor in a rat model or autoimmune myasthenia gravis; implication for the design of specific immunotherapies. Clin Exp Immunol 1995; 102:462-7.
36. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and nature recovery from experimental allergic encephalomyelitis are associated with downregulation of inflammatory cytokines and upregulation of TGF-β. IL-4 and prostaglandin E expression in the brain. J Exp Med 1992; 176:1355-64.
37. Husby S, Mesterdy J, Holland S, Elson CO. Oral tolerance in humans: T cell but not B tolerance after feeding. J Immunol 1994; 152:4664-70.
38. Burstein HJ, Shea CM, Abbas AK. Aqueous antigens induce in vivo tolerance selectively in IL-2 and IFN-gamma-producing cells. J Immunol 1992; 148:3687-91.
39. Melamed D, Fredman A. In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression. Eur J Immunol 1994; 24:1974-81.
40. Link H, Olsson O. Sun JB et al. Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls. J Clin Invest 1991; 87:2191-6.
41. Link J. Söderström M. Ljungdahl A et al. Organ-specific autoantigens induce IFN-γ and IL-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurol 1994; 44:728-35.
42. Matusevicuis D, Navikas V, Palask W, Pirskanen R, Fredrikson S. Link H. Tumor necrosis factor-α, lymphotoxin, interleukin (IL,)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis. J Neuroimmunol 1996; 71:191-8.
43. Shi FD, Zhang GX, Bai XF, van der Meide PH, Link H. Cellular mRNA expression of IFN-γ, IL-4 and IL-10 related to resistance to experimental autoimmune myasthenia gravis in young Lewis rats. Clin Exp Immunol 1997; 108:523-7.
44. Ahlberg RE, Pirskanen R, Lefvert AK. Defective T lymphocyte function in nonthymectomized patients with myasthenia gravis. Clin Immunol Immunopathol 1991; 60:93-100.
45. Gu D, Wogensen I, Calcutt NA et al. Myasthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J Exp Med 1995; 181:547-57.
46. Zhang GX, Xiao BG, Bai XF, Örn A. Van der Meide PH, Link H. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol, in press.
47. Balasa B, Deng CS, Christadoss P, Bradley LM, Sarvetnick N. IFN-γ is necessary for the genesis of acetylcholine receptor induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 1997; 168:385-91.
48. Graus YME, van Breda Vriesman PJC, De Baets MH, Characterization of anti-AChR antibodies from mice differing in susceptibility for experimental autoimmune myasthenia gravis. Clin Exp Immunol 1993; 92:506-13.
49. Krolick KA, Zoda TE, Thompson PA. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv Neuroimmunol 1994; 4:475-93.
50. Sidman CL, Marshall JD, Shultz LD, Gray PW, Johson HM. γ-interferon is one of the several direct B cell-maturing lymphokines. Nature 1984; 309:801-3.
51. Snapper CM, Mond JJ. Toward a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14:15-17.
52. Rizzo IV, DeKruyff RH, Umetsu DT. Generation of B cell memory and affinity maturation: induction with Th1 and Th2 cell clones. J Immunol 1992; 148:3733-8.
53. Jelinek DF, Lipsky PE. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor alpha and interleukin I. J Immunol 1987; 139:2970-9.
54. Keller R, Keist R, Bazin H, Joller P, Van der Meide PH. Binding of monomeric immunoglobulins by bone marrow-derived mononuclear phagocytes; its modulation by interferon-gamma. Eur J Immunol 1990; 20:2137-40.